Kaplan-Meier: Time to First Occurrence of a MACE in the SUSTAIN 6 Trial The treatment effect for the primary composite endpoint and its components in the SUSTAIN 6 trial is shown in Table 8
Accounts of people knocking off the pounds using the drug have contributed to a spiking demand and shortages
[2] According to NHS guidance, symptoms of DKA include excessive thirst, frequent urination, nausea, vomiting, abdominal pain, confusion, or unusual fatigue
Two-side p-values are reported
In these trials, semaglutide was shown to lower A1C levels by about 1% to 2%, while Tirzepatide provided a slightly greater reduction of 2% to 2.5%
The gradual decline in diabetic patients begins with diabetes-associated cognitive decrements, progressing to mild cognitive impairment, and eventually leading to dementia